Bloodstream Infections Caused by ESBL-Producing E. coli and K. pneumoniae: Risk Factors for Multidrug-Resistance

被引:32
作者
Serefhanoglu, Kivanc [1 ]
Turan, Hale [1 ]
Timurkaynak, Funda Ergin [1 ]
Arslan, Hande [1 ]
机构
[1] Baskent Univ, Fac Med, Dept Infect Dis & Clin Microbiol, TR-06490 Ankara, Turkey
关键词
ESBLs; multidrug resistance; risk factors; SPECTRUM BETA-LACTAMASES; KLEBSIELLA-PNEUMONIAE; ESCHERICHIA-COLI; SURVEILLANCE PROGRAM; MOLECULAR EPIDEMIOLOGY; ENTEROBACTERIACEAE; PREVALENCE; HOSPITALS; TAIWAN; SYSTEM;
D O I
10.1590/S1413-86702009000600003
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This prospective case-control study was conducted from October 2003 to June 2007 to evaluate risk factors for multidrug resistance among extended-spectrum-b-lactamase-producing Escherichia coli and Klebsiella spp. (ESBL-EK) isolates in blood cultures. All adult patients (>= 18 years old) whose blood cultures grew ESBL-EK during the study period were included. An ESBL-EK isolate was defined as MDR if it was resistant to at least one member of following two classes of antibiotics: aminoglycosides (amikacin, gentamicin, or netilmycin) and fluoroquinolones (ofloxacin, or ciprofloxacin). Case patients were those with a MDR ESBL-EK isolate, and control patients were those with a non-MDR ESBL-EK isolate. A total of 94 bloodstream infections, including 37 (39,4%) bloodstream infections with ESBL-producing E. coli and 57 (60,6%) with ESBL-producing K. pneumoniae, in 86 patients were enrolled. Thirty episodes (31.9%) were due to MDR ESBL-EK. The only independent risk factor for MDR ESBL-EK was duration of hospitalization before bacteraemia (OR 3.88; 95% CI 1.55-9.71; p=0.004). The rate of multidrug resistance among ESBL-EK bloodstream isolates was high, and duration of hospitalization before bacteraemia was the only indeepended risk factor for the MDR ESBL-EK bloodstream infections.
引用
收藏
页码:403 / 407
页数:5
相关论文
共 32 条
[1]   Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum β-lactamases [J].
Ali Shah, A ;
Hasan, F ;
Ahmed, S ;
Hameed, A .
RESEARCH IN MICROBIOLOGY, 2004, 155 (06) :409-421
[2]  
[Anonymous], 1999, M100S9 NAT COMM CLIN
[3]  
BAUER AW, 1966, AM J CLIN PATHOL, V45, P493
[4]   Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa:: regional results from SENTRY Antimicrobial Surveillance Program (1998-99) [J].
Bell, JM ;
Turnidge, JD ;
Gales, AC ;
Pfaller, MA ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 42 (03) :193-198
[5]   Influx of extended-spectrum β-lactamase producing enterobacteriaceae into the hospital [J].
Ben-Ami, R ;
Schwaber, MJ ;
Navon-Venezia, S ;
Schwartz, D ;
Giladi, M ;
Chmelnitsky, I ;
Leavitt, A ;
Carmeli, Y .
CLINICAL INFECTIOUS DISEASES, 2006, 42 (07) :925-934
[6]  
Blank Rebecca M., 2004, M100S14 NAT COMM CLI, P24
[8]  
Chlebicki MP, 2004, ANN ACAD MED SINGAP, V33, P302
[9]   Evolution and dissemination of extended-spectrum β-lactamase-producing Klebsiella pneumoniae:: Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003) [J].
DiPersio, JR ;
Deshpande, LM ;
Biedenbach, DJ ;
Toleman, MA ;
Walsh, TR ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 51 (01) :1-7
[10]   Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? [J].
Falagas, Matthew E. ;
Bliziotis, Ioannis A. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (06) :630-636